Health Condition 1: null- Diagnosed cases of Ankylosing Spondylitis (AS) or Psoriatic Arthritis (PA) who are refractory to conventional therapy.
Conditions
Interventions
None listed
Sponsors
Department of Pharmacology Institute of Postgraduate Medical Education and Research Kolkata
Eligibility
Inclusion criteria
Inclusion criteria: 1. Adult patients of age between 18-60 years of either gender clinically diagnosed as cases of Ankylosing Spondylitis or Psoriatic arthritis who have been advised TNF alpha inhibitor (Infliximab or Adalimumab) therapy as per institutional treatment protocol. 2. Patients who satisfy eligibility criteria for getting TNF alpha inhibitors. 3. Subjects willing to give written informed consent and comply with study related instructions.
Exclusion criteria
Exclusion criteria: 1. Patients of Ankylosing Spondylitis or Psoriatic arthritis having any clinical condition were TNF alpha inhibitor (Infliximab or Adalimumab) therapy is contraindicated. 2. Subjects unwilling to give written informed consent and comply with study related instructions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| For AS cases 50% reduction in a baseline BASDAI Score (or absolute reduction of 2 out of 10) and favourable Expert Opinion For Psoriatic arthritis, reduction in Disease Activity Index for Psoriatic Arthritis (DAPSA) and favourable Expert opinion Timepoint: 6 months from the initiation of therapy | — |
Secondary
| Measure | Time frame |
|---|---|
| Improvement in both objective and subjective indicators of disease activity and functionTimepoint: 6 months from the initiation of therapy | — |
Countries
India
Contacts
Public ContactDr Pradipta Das
Institute of Postgraduate Medical Education and Research,Kolkata
Outcome results
None listed